SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses and the development of new variant-derived vaccines.
When to update COVID-19 vaccine composition
Vaccines against different SARS-CoV-2 variants have been approved, but continued surveillance is needed to determine when the antigen composition of vaccines should be updated, together with clinical studies to assess vaccine efficacy.
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has been dominant in Europe since January 2022, causing large waves of infections because of high transmissibility and escape from vaccine- and infection-induced immunity.
Current COVID-19 situation and what's next for COVID-19
WHO's Information Network for Epidemics organised a webinar to provide an update on the current COVID-19 situation, the new variants, and discuss what it means for the pandemic and our lives.
